National
AIDS group criticizes Obama as int’l conference approaches
Others praise administration, call attacks ‘misplaced’
Tom Myers, chief of public affairs and general counsel for the AIDS Healthcare Foundation (Blade photo by Michael Key)
President Obama is facing criticism from an HIV/AIDS group for not yet committing to speak at the upcoming International AIDS Conference and not doing more to confront the global and domestic epidemic. Other groups, meanwhile, are calling the criticism of Obama misguided.
On Monday, the AIDS Healthcare Foundation held a news conference in D.C. at the offices of Parry, Romani, DeConcini & Symms Associates to call on Obama to speak at the conference and take more action to confront HIV/AIDS. The organization provides advocacy and medical care to more than 166,000 people with HIV/AIDS in 26 countries.
Tom Myers, chief of public affairs and general counsel for the AIDS Healthcare Foundation, was particularly critical of Obama for not yet confirming that he’ll make an appearance at the upcoming 19th International AIDS Conference, which will will take place at D.C.’s Walter E. Washington Convention Center during the week of July 22.
“We are here to express our concern and dismay that, less than two weeks from the start of the conference, President Obama has yet to commit to attending it,” Myers said. “In the 20-odd year history of this conference, it is virtually obligatory for the head of state of the host nation to address the conference at its opening.”
It’s the first time since 1990 that the conference will take place in the United States. Organizers agreed to hold the conference in D.C. after the lifting of the HIV travel ban in 2009, which had prevented HIV-positive foreign nationals from entering the United States. The process for removing the ban started under the Bush administration through legislative action and ended under the Obama administration.
As of Monday, the conference hadn’t yet announced whether it had received confirmation that Obama would speak. Shin Inouye, a White House spokesperson, said he had no updates on whether Obama will attend the conference.
Former President Bill Clinton has agreed to speak at the conference this year as well as former first lady Laura Bush. High-ranking administration officials who are set to speak include Secretary of Health & Human Services Kathleen Sebelius and Eric Goosby, U.S. Global AIDS Coordinator.
It’s not unprecedented for the head of state to be absent from the conference, according to organizers. The Canadian prime minister didn’t speak when the conferences were held in that country in 1996 in Vancouver or 2006 in Toronto, nor did Spain’s prime minister attend the 2002 conference in Barcelona. In 1990, then-President George H.W. Bush didn’t address the conference in San Francisco, but then-Secretary of Health & Human Services Louis Sullivan delivered remarks at the closing ceremony.
While criticizing Obama for not confirming his attendance, Myers at the same time said the administration wasn’t doing enough to confront HIV/AIDS and said “it may be better if the president not attend the conference if he is coming without any concrete proposals to fix these problems.”
For starters, Myers criticized the president for cutting funds in the fight against the global AIDS epidemic, calling on Obama to restore the money that was cut from PEPFAR, as part of the fiscal year 2013 budget request.
“Internationally, the Obama administration is the first administration to actually propose cutting funding to America’s efforts, including cutting almost half a billion dollars from PEPFAR, the President’s Emergency Plan for AIDS Relief,” Myers said. “A retreat in the efforts to fight the global epidemic is unprecedented.”
The sentiment that Obama has taken a step back in global fight against HIV/AIDS was echoed by Omonigho Ufomata, the AIDS Healthcare Foundation’s director of global policy and advocacy.
“We demand he restore funding to PEPFAR and expand treatment prior to addressing the International AIDS Conference,” Ufomata said. “We have a blueprint for stopping AIDS, i.e get more people on treatment, but that can only be achieved if President Obama gets real about the money.”
Further, Myers faulted Obama for not providing enough support to the AIDS Drug Assistance Program, the primary program for providing lifesaving HIV/AIDS drugs to low-income people, saying the wait list for the programs stands at 2,000 people.
“Domestically, President Obama has presided over the longest and deepest waiting lists for the AIDS Drug Assistance Program, or ADAP in history,” Myers said. “ADAP is the primary program for providing lifesaving HIV/AIDS drugs to uninsured people of limited means in this country and for years, thousands of people, at one point almost 10,000 people, have had to wait to receive these drugs.”
Myers called on Obama to redirect funds within the Department of Health & Human Services “to immediately end the ADAP waitlists once and for all.”
Despite these criticisms, Obama has generally received praise for his work on HIV/AIDS. On World AIDS Day in December, President Obama announced an additional $35 million for the ADAP program and $15 million more for Part C of the Ryan White Care Program as well as a three-year, $4 billion pledge to the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Additionally, under the FY-13 budget request, funding for the Ryan White AIDS Drug Assistance Program would increase by $75 million. The budget also bumps up $1 billion for AIDS drug assistance programs, an increase of $67 million above the previous fiscal year’s levels. The administration is predicting this funding will end ADAP waiting lists next year.
A White House official, speaking on condition of anonymity, said PEPFAR is able to accomplish more with less money in previous years as the number of people the United States directly supports with lifesaving antiretroviral treatment has more than doubled from around 1.7 million to more than 3.9 million.
“PEPFAR continues to improve efficiency and lower costs,” the official said. “By using generic drugs, shipping commodities more cheaply, task-shifting to nurses and community health workers as appropriate, and linking AIDS services to other programs (such as maternal and child health), the per-patient cost to the U.S. of providing anti-retroviral treatment for AIDS patients has fallen by over 50 percent since 2008.”
Based on this commitment, the leaders of other HIV/AIDS groups said they didn’t share the criticisms levied against Obama by the AIDS Healthcare Foundation.
Carl Schmid, deputy executive director of the AIDS Institute, said he’s still hoping Obama will make an appearance at the AIDS conference, but believes the criticism is “misplaced” and should be directed elsewhere.
“We feel the president has been leading on domestic AIDS and has put forth an ambitious National HIV/AIDS Strategy, passed health care reform, and proposed budget increases for ADAP and HIV prevention,” Schmid said. “While he could always do more, we feel the criticism is misplaced and instead the focus should be on some members of the Congress, many of whom want to repeal health reform and cut funding to AIDS programs.”
Chris Collins, vice president and director of public policy for the Foundation for AIDS Research, or amfAR, said Obama has “greatly advanced” the domestic response to HIV.
“His national strategy, the Affordable Care Act — these are game changers in the domestic epidemic, so we should be proud of what the president has done on domestic AIDS,” Collins said.
Collins added he wants “to see increases” in PEPFAR funding, but said Obama has made historic commitments to the Global Fund to Fight AIDS, Tuberculosis, and Malaria and “new and more substantial commitments in terms of scaling up services.”
Asked by the Washington Blade during the news conference if Obama deserves credit for increasing funds for the Ryan White Care Program, Myers said Obama deserves some praise, but more is needed.
“The problem is, again, even with that, the ADAP waiting list – and ADAP is a part of the Ryan White Program — it’s chronic, it’s ongoing. … So, again, increases that have occurred, credit is where credit is due, but the point is, it is not enough,” Myers said.
Michael Weinstein, president of the AIDS Healthcare Foundation, who joined the conference via telephone, dismissed Obama’s increase in funds for the Ryan White Care Program on the basis that a minority percentage of people with HIV/AIDS are in regular care under the program.
“We are sending out a really mixed message when we have more waiting lists for these drug programs and we’re telling people that they should be tested,” Weinstein said. “I mean, why would they want to get tested when they don’t know if they can have access to treatment? But the bottom line is that to have only 41 percent of people in routine care and having more than 600,000 people who either don’t know that they’re positive or are not in routine care is not a success.”
Weinstein added his organization has tried “without a lot of success” to enlist help from the administration in bringing down the cost of medications, saying the federal government could offer more support “in negotiations with the drug companies to make these drugs more accessible.”
Blade photo editor Michael Key contributed to this report.
CORRECTION: An initial version of this article misquoted the AIDS Institute’s Carl Schmid as saying the AIDS Healthcare Foundation’s criticisms of Obama were “misguided.” The word he used was “misplaced.” The Blade regrets the error.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
Advocates say MTG bill threatens trans youth, families, and doctors
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Far-right José Antonio Kast elected Chile’s next president
Lighting candles in a time of exhaustion
In real estate, trust the process
-
Politics2 days agoLGBTQ Democrats say they’re ready to fight to win in 2026
-
District of Columbia2 days ago
Brian Footer suspends campaign for Ward 1 D.C. Council seat
-
Chile5 days ago
Far-right José Antonio Kast elected Chile’s next president
-
Opinions3 days ago
Lighting candles in a time of exhaustion
